Pipeline Expanded with Proprietary Injectable Antipsychotic
Filed with ASX · · 8 pages · English
Summary by 6ix AI
Patrys Limited has announced the acquisition of Reliis Pty Ltd, a clinical-stage pharmaceutical company, to expand its pipeline with a proprietary injectable antipsychotic targeting the delirium market. This acquisition aims to reduce development risk and enhance Patrys' portfolio by adding a near-term, lower-risk pharmaceutical asset alongside its existing biologics program. The filing outlines the strategic rationale for the acquisition, emphasizing the potential for accelerated regulatory pathways and value creation for shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Patrys
- Trading Halt
- Appendix 4C - Quarterly - 30 September 2025
- Patrys Receives R&D Tax Incentive Refund
- Notice of Annual General Meeting/Proxy Form
- Appendix 4E - Preliminary Final Report
Later from Patrys
- Completion of Acquisition and Board Appointments
- Investor Presentation
- Appendix 4C - Quarterly - 31 December 2025
- Appointment of Chief Executive Officer
- Appendix 4D - Half Year Accounts - 31 December 2025
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys